This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blansfield, J. A. Articles by Libutti, S. K. Search for Related Content PubMed PubMed Citation Articles by Blansfield, J. A. Articles by Libutti, S. K.

Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy

Authors' Affiliations: ¹ Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland and ² Celgene Corporation, Summit, New Jersey

Requests for reprints: Joseph A. Blansfield, Surgery Branch, National Cancer Institute, NIH, 10 Center Drive, CRC 3-3940, Bethesda, MD 20892. Phone: 3014433545; Fax: 3014803825; E-mail: jblansfield1{at}geisinger.edu.

Purpose: Over the past 60 years, cytotoxic chemotherapy has targeted the cancer cell. Despite this, there have been few cancer cures. A new approach to cancer therapy is to target the multicellular biological entity of the tumor microenvironment.

Experimental Design: Lenalidomide, an immunomodulatory drug, sunitinib, a tyrosine kinase inhibitor, and low-dose metronomic cyclophosphamide, were tested alone and in combination for their abilities to inhibit endothelial cell tube formation, rat aortic ring outgrowth, tumor growth, and metastatic development in mice. In addition, ectopic tumor lysates were evaluated for the presence of proangiogenic proteins.

Results: The three agents alone were shown to significantly inhibit endothelial cells' ability to form tubes and significantly inhibit the multicellular microenvironment in the rat aortic ring assay (P < 0.01 and P < 0.001). This effect was also significantly augmented when the agents were combined. Furthermore, the three-drug combination was able halt the progression of tumor growth almost completely in xenograft models of ocular melanoma, colon cancer, pancreatic cancer, and cutaneous melanoma. These agents significantly decrease the number of proliferating cells in tumors, significantly increase the number of cells undergoing active cell death in tumors, and significantly decrease the number of blood vessels in treated tumors (P < 0.05). Combination therapy shows a decrease in the compensatory up-regulation of proangiogenic proteins after treatment when compared with single-agent therapy.

Conclusions: This combination of agents causes an inhospitable microenvironment for tumor cells and shows great promise for use in the clinic.

This article has been cited by other articles:

				R. C Smallridge, L. A Marlow, and J. A Copland Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies Endocr. Relat. Cancer, March 1, 2009; 16(1): 17 - 44. [Abstract] [Full Text] [PDF]

				H.-C. J. Shen, M. He, A. Powell, A. Adem, D. Lorang, C. Heller, A. C. Grover, K. Ylaya, S. M. Hewitt, S. J. Marx, et al. Recapitulation of Pancreatic Neuroendocrine Tumors in Human Multiple Endocrine Neoplasia Type I Syndrome via Pdx1-Directed Inactivation of Men1 Cancer Res., March 1, 2009; 69(5): 1858 - 1866. [Abstract] [Full Text] [PDF]

				M. Kwon, E. Hanna, D. Lorang, M. He, J. S. Quick, A. Adem, C. Stevenson, J.-Y. Chung, S. M. Hewitt, E. Zudaire, et al. Functional Characterization of Filamin A Interacting Protein 1-Like, a Novel Candidate for Antivascular Cancer Therapy Cancer Res., September 15, 2008; 68(18): 7332 - 7341. [Abstract] [Full Text] [PDF]